Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and ...
tylerpaper.com
news
2022-10-21 13:05:48

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming poster presentations at The Liver MeetingÂ® (November 4-8, 2022), hosted by the American Association for the Study of Liver Diseases (AASLD).All posters, which cover drug candidates targeting chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH), will be available on the Aligos website at Scientific Presentations & Conferences following the conclusion of the conference.
